Medication info
Ferbon Tablet (Polyneate Calcium)

Ferbon Tablet (Polyneate Calcium)

Prescription medicationTablet
Ingredient · strength
Calcium Folinate›5.4mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
White to whitish round tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 199001319 · Notified 1990.11.23 · Insurance code 647802460

Summary

Main use
Relief of toxicity from folate antagonists
Who uses it
Adults
Adult dosage
(Injection) 1. Conventional methotrexate therapy: If adverse reactions occur with the usual dose of methotrexate (a folic acid antagonist), administer 6-12mg of folinate per dose by intramuscular injection 4 times daily, every 6 hours. In the event of methotrexate overdose, administer an amount equal to the methotrexate dose given. 2. Methotrexate-folinate rescue therapy: Starting 3 hours after completion of methotrexate administration, administer 15mg of folinate per dose by intravenous injection every 3 hours for 9 doses, followed by intravenous or intramuscular injection every 6 hours for 8 doses. If severe adverse reactions thought to be due to methotrexate occur, increase the dose and extend the treatment period. 3. Combination therapy with 5-Fluorouracil (5-FU) for advanced colorectal cancer: Select one of the two regimens. 1) Administer 200mg/㎡ of calcium folinate slowly by intravenous injection over at least 3 minutes once daily, followed by intravenous injection of 370mg/㎡ of 5-FU. 2) Administer 20mg/㎡ of calcium folinate intravenously once daily, followed by intravenous injection of 425mg/㎡ of 5-FU. Do not administer them simultaneously, as precipitation of 5-FU and folinate may occur. Continue the above treatment for 5 days and repeat every 4 weeks. (Tablets) In the event of overdose of a folic acid antagonist (e.g., methotrexate), administer 10mg of folinate per m2 of body surface area orally every 6 hours as soon as possible (within 1 hour after the overdose) to reduce the serum methotrexate concentration to 10-8M/L or less. If gastrointestinal toxicity, nausea, or vomiting occurs, administer folinate parenterally. Analyze serum every 24 hours to determine creatinine and methotrexate concentrations. If the serum creatinine concentration 24 hours later has increased by 50% compared with the concentration before methotrexate administration, or if the serum methotrexate concentration at 24 hours is 5X10-6M/L or higher, administer a high dose of calcium folinate. Oral doses of 25mg or more are not recommended; administer parenterally. Maintain urine output of 1800-2000mL/㎡ per day by administering fluids, while alkalinizing the urine with sodium bicarbonate (maintain urine pH at 7.0 or higher) to increase the solubility of methotrexate and its metabolites until the methotrexate level reaches 5×10-8M/L(0.05μM/L).

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Relief of toxicity from folate antagonists

  • Toxicity of folate metabolism antagonists
View approved original text

This injection helps reduce the toxicity of folate metabolism antagonists and is used in combination with 5-Fluorouracil (5-FU) during the treatment of metastatic colorectal cancer to enhance therapeutic effects. It is also utilized in tablet form to reduce the toxicity of folate metabolism antagonists. This medication plays an important role in alleviating side effects and enhancing therapeutic effects, especially during cancer treatment. Thus, this injection is used for the mitigation of toxicity associated with folate metabolism antagonists and the treatment of colorectal cancer.

Dosage and Administration

Adult dosage

(Injection) 1. Conventional methotrexate therapy: If adverse reactions occur with the usual dose of methotrexate (a folic acid antagonist), administer 6-12mg of folinate per dose by intramuscular injection 4 times daily, every 6 hours. In the event of methotrexate overdose, administer an amount equal to the methotrexate dose given. 2. Methotrexate-folinate rescue therapy: Starting 3 hours after completion of methotrexate administration, administer 15mg of folinate per dose by intravenous injection every 3 hours for 9 doses, followed by intravenous or intramuscular injection every 6 hours for 8 doses. If severe adverse reactions thought to be due to methotrexate occur, increase the dose and extend the treatment period. 3. Combination therapy with 5-Fluorouracil (5-FU) for advanced colorectal cancer: Select one of the two regimens. 1) Administer 200mg/㎡ of calcium folinate slowly by intravenous injection over at least 3 minutes once daily, followed by intravenous injection of 370mg/㎡ of 5-FU. 2) Administer 20mg/㎡ of calcium folinate intravenously once daily, followed by intravenous injection of 425mg/㎡ of 5-FU. Do not administer them simultaneously, as precipitation of 5-FU and folinate may occur. Continue the above treatment for 5 days and repeat every 4 weeks. (Tablets) In the event of overdose of a folic acid antagonist (e.g., methotrexate), administer 10mg of folinate per m2 of body surface area orally every 6 hours as soon as possible (within 1 hour after the overdose) to reduce the serum methotrexate concentration to 10-8M/L or less. If gastrointestinal toxicity, nausea, or vomiting occurs, administer folinate parenterally. Analyze serum every 24 hours to determine creatinine and methotrexate concentrations. If the serum creatinine concentration 24 hours later has increased by 50% compared with the concentration before methotrexate administration, or if the serum methotrexate concentration at 24 hours is 5X10-6M/L or higher, administer a high dose of calcium folinate. Oral doses of 25mg or more are not recommended; administer parenterally. Maintain urine output of 1800-2000mL/㎡ per day by administering fluids, while alkalinizing the urine with sodium bicarbonate (maintain urine pH at 7.0 or higher) to increase the solubility of methotrexate and its metabolites until the methotrexate level reaches 5×10-8M/L(0.05μM/L).

Precautions

This medication is not suitable for the treatment of pernicious anemia due to vitamin B12 deficiency or other macrocytic anemias. Even if neurological symptoms continue to progress, attention is required as hematological status may improve. In the case of injection form, when opening the ampoule, glass fragments may be mixed, so caution should be exercised during use, especially when administering to children or the elderly. Women who are pregnant or breastfeeding should avoid using this medication, and careful consideration should be given in certain situations. This medication may cause side effects such as hypersensitivity reactions, urticaria, temporary pain at the injection site, fever, central nervous system disorders (paralysis, excitement, depression). Also, interactions with other drugs may lead to various adverse reactions such as diarrhea, skin reactions, oral mucositis, so caution is necessary. This medication should be used under the guidance of a physician experienced in chemotherapy, and blood concentrations should be measured during treatment to determine appropriate dosage and treatment duration. If renal function is impaired or bodily fluids are abnormally accumulated, drug excretion may be delayed, necessitating dosage adjustment. This medication may interact with certain anticancer drugs, reducing their effects or increasing side effects, so it is essential to discuss the concurrent medications with a physician. Pregnant or breastfeeding women should only use this medication if absolutely necessary, and should not be administered in combination with 5-FU. Elderly patients require careful observation due to decreased bodily function and increased side effects risk. This medication is contraindicated for intrathecal administration. When administering intravenously, the infusion rate should be limited to below 160mg per minute due to calcium content. Keep this medication out of the reach of children and store it in the original container to prevent degradation in quality or misuse.

Side effects

  • Anaphylactic reactions
  • urticaria
  • vascular pain
  • transient pain
  • fever
  • neuropathy
  • agitation
  • depression
  • diarrhea
  • skin reactions
Show 6 more
  • skin dryness
  • stomatitis
  • conjunctivitis
  • mucositis
  • mild hematologic toxicity
  • leucopenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container that blocks light and prevents air from entering. The storage temperature should be maintained at room temperature between 1 degree and 30 degrees.

Appearance and packaging

Appearance

White to whitish round tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.